Russell Investments Group Ltd. Purchases 114,730 Shares of AbbVie Inc. $ABBV

Russell Investments Group Ltd. raised its position in AbbVie Inc. (NYSE:ABBV) by 7.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,621,115 shares of the company’s stock after acquiring an additional 114,730 shares during the period. Russell Investments Group Ltd. owned about 0.09% of AbbVie worth $408,561,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ABBV. Brighton Jones LLC raised its stake in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. boosted its stake in AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after buying an additional 789 shares in the last quarter. Ieq Capital LLC increased its holdings in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after buying an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC increased its holdings in AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after buying an additional 612,702 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Humira replacement strategy is gaining credibility: second-quarter revenue rose 10.2% to $16.99 billion, led by immunology products and supported by neuroscience. This suggests Skyrizi, Rinvoq and other newer medicines are more than offsetting Humira’s biosimilar-related decline. AbbVie’s Humira Replacement Strategy Is Working
• Positive Sentiment: New lung-cancer data for investigational treatments ABBV-1480, ABBV-706 and Temab-A point to potentially meaningful future growth in oncology. Reported response rates and manageable safety profiles strengthen the case for AbbVie’s longer-term pipeline, though the programs remain dependent on additional clinical results and approvals. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
• Positive Sentiment: Several investment managers increased their AbbVie holdings, including Convergence Financial, which nearly doubled its position, and Donaldson Capital Management, which modestly raised its stake. These filings provide a supportive institutional signal but are not major earnings catalysts. Convergence Financial Increased Its AbbVie Holdings
• Neutral Sentiment: In comparisons with Eli Lilly, AbbVie offers a more established cash-generating portfolio and attractive pipeline opportunities, while Lilly has stronger headline growth prospects. The debate highlights AbbVie’s balance between income, stability and pipeline execution rather than a clear near-term catalyst. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
• Negative Sentiment: Second-quarter oncology sales declined 2.4% as Imbruvica continued to weaken. Growth from Venclexta and newer medicines partly offset the pressure, but the result underscores ongoing reliance on successful launches and pipeline products to revive the franchise. How Did AbbVie’s Oncology Sales Hold Up in Q2?

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the subject of a number of analyst reports. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Wells Fargo & Company upped their target price on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Guggenheim increased their price target on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Barclays raised their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Canaccord Genuity Group lifted their price objective on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $265.56 on Wednesday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The business has a fifty day moving average of $250.20 and a two-hundred day moving average of $228.12. The stock has a market cap of $469.18 billion, a PE ratio of 75.02, a PEG ratio of 0.88 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.